沙丁胺醇、布地奈德不同雾化吸入联合头孢哌酮钠舒巴坦钠对AECOPD患者血气指标和肺功能的影响

目的:探讨沙丁胺醇、布地奈德不同雾化吸入联合头孢哌酮钠舒巴坦钠对慢性阻塞性肺疾病急性加重期(AECOPD)患者血气指标和肺功能的影响。方法:选取本院2015年1月至2018年10月期间收治的210例AECOPD住院患者作为研究对象,随机分为对照组(头孢哌酮钠舒巴坦钠治疗)、持续雾化组(沙丁胺醇、布地奈德持续雾化治疗+头孢哌酮钠舒巴坦钠)、先后雾化组(先给予沙丁胺醇雾化、后给予布地奈德雾化治疗+头孢哌酮钠舒巴坦钠),每组各70例,对比三组的临床疗效、血气指标、肺功能及不良反应。结果:先后雾化组总有效率为91.43%,高于持续雾化组的78.57%及对照组的67.14%(P0.05)。先后雾化组患者治疗5天后氧分压(PaO_2)、氧饱和度(SaO_2)高于持续雾化组及对照组,且持续雾化组高于对照组(P0.05);先后雾化组患者治疗5天后二氧化碳分压(PaCO_2)低于持续雾化组及对照组,且持续雾化组低于对照组(P0.05)。先后雾化组患者第一秒用力呼气容积(FEV_1)、用力肺活量(FVC)、第一秒用力呼吸容积占用力肺活量的百分比(FEV_1/FVC%)、第一秒用力呼气容积占预计值百分比(FEV_1%)高于持续雾化组及对照组,且持续雾化组高于对照组(P0.05)。三组不良反应总发生率比较无统计学差异(P0.05)。结论:沙丁胺醇、布地奈德先后雾化吸入联合头孢哌酮钠舒巴坦钠治疗AECOPD患者疗效确切,可提高患者肺功能,改善血气相关指标。

Effects of Different Aerosol Inhalation of Salbutamol and Budesonide Combined with Cefoperazone Sodium and Sulbactam Sodium on blood Gas Index and Lung Function in Patients with AECOPD

ABSTRACT Objective: To investigate the effects of different aerosol inhalation of salbutamol and budesonide combined with cefoperazone sodium and sulbactam sodium on blood gas index and lung function in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods: 210 AECOPD inpatients who were admitted to our hospital from January 2015 to October 2018 were selected as the study subjects. They were randomly divided into control group (cefoperazone sodium sulbactam sodium treatment), continuous atomization group (salbutamol, budesonide continuous atomization treatment+cefoperazone sodium sulbactam sodium), and successive atomization group (salbutamol atomization, budesonide atomization treatment+cefoperazone sodium sulbactam sodium). 70 cases in each group. The clinical efficacy, blood gas index, lung function and adverse reactions of the three groups were compared. Results: The total effective rate of successive atomization group was 91.43%, which was higher than that of continuous atomization group (78.57%) and control group (67.14%) (P<0.05). The partial pressure of oxygen (PaO₂) and oxygen saturation (SaO₂) in the successive atomization group were higher than those in the continuous atomization group and the control group at 5 days after treatment, and that in the continuous atomization group was higher than that in the control group (P<0.05). The partial pressure of carbon dioxide (PaCO₂) in the successive atomization group at 5 days after treatment was lower than that in the continuous atomization group and the control group, and that in the continuous atomization group was lower than that in the control group (P<0.05). The first second forced expiratory volume (FEV₁), forced vital capacity (FVC), the percentage of forced expiratory volume occupied by the first second forced expiratory volume (FEV₁/FVC), and the percentage of forced expiratory volume occupied by the first second forced expiratory volume (FEV₁%) in the successive atomization group were higher than those in the continuous atomization group and the control group. Those in the continuous atomization group were higher than those in the control group (P<0.05). There was no significant difference in the total incidence of adverse reactions among the three groups (P>0.05). Conclusion: Salbutamol, budesonide atomization inhalation combined with cefoperazone sodium and sulbactam sodium in the treatment of AECOPD patients is effective, it can improve the lung function of patients, improve blood gas related indicators.